HPN217 is a BCMA-targeting tri-specific t-cell activating construct (TriTAC) in development for patients with multiple myeloma.

SparkCures ID 367
Developed By Harpoon Therapeutics
Generic Name HPN217
Treatment Classifications
  • Trispecific Antibody
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)